NASDAQ$TERN

Terns Pharmaceuticals Inc · Q4 2026 earnings

Q4 2026 earnings · · After market close · Investor relations

Reports awaiting report

Terns hasn't published Q4 2026 actuals yet. The tiles below frame what to compare against; sections further down are historical context only.

  • Most recent report

    Q3 2025

    Revenue
    $0.00
    EPS
    -$0.27
  • FY2026 consensus

    Analyst consensus

    Revenue
    $2.4M
    EPS
    -$1.46

Revenue & EPS history

Terns · Revenue · Quarterly

$0

Q3 2025

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q4 2026

Historical avgQ4 2026

-0.3%

Avg return

Earnings day

+0.9%

Avg return

5 days after

+16.4%

Avg return

30 days after

48%

10 / 21 earnings

Positive

+19.8%

Q4 2022

Best reaction

-23.0%

Q3 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2026-1.3%-0.0%
Q3 2025+7.6%+18.0%+146.3%
Q2 2025-6.8%+3.6%+18.7%
Q1 2025-0.7%-4.1%+22.3%
Q4 2024-2.7%-1.3%-23.6%
Q3 2024-9.1%-17.3%-11.7%
Q2 2024-4.6%-11.8%-1.7%
Q1 2024+7.7%+6.1%+32.9%
Q4 2023+1.7%-15.0%-27.4%
Q3 2023+14.2%+10.1%+92.3%
Q2 2023-9.5%+0.8%-21.5%
Q1 2023-15.2%-20.3%-7.0%
Q4 2022+19.8%+32.7%+42.3%
Q3 2022-23.0%-26.7%-12.2%
Q2 2022-5.5%+39.2%+75.1%
Q1 2022+4.0%-0.7%+26.5%
Q4 2021+4.1%+3.5%-5.4%
Q3 2021-1.2%-5.9%-30.9%
Q2 2021+4.3%+3.5%-0.9%
Q1 2021+3.6%+5.6%+13.5%
Q4 2020+5.8%-0.9%+1.2%
Q3 2020
Q2 2020
Q1 2020
Q4 2019

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro